Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica J Lin

Showing results (21-30 of 92) with videos related to

Pageof 10
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 12, 2018
Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS MetastasesJessica J Lin, Ginger Y Jiang, Nencyben Joshipura, et al.
JTO Clinical and Research Reports|August 18, 2025
Role of Quality of Life in Daily Functioning, Communication with Care Teams, and Treatment Decisions in Patients with <i>ALK</i>+ NSCLCHeather Law, Huamao M Lin, Eileen Curran, et al.
NPJ Precision Oncology|November 4, 2023
Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolutionJaime L Schneider, Khvaramze Shaverdashvili, Mari Mino-Kenudson, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2024
Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancerJessica R Bauman, Geoffrey Liu, Isabel Preeshagul, et al.
Experimental Hematology & Oncology|October 22, 2019
Identification of osimertinib-resistant <i>EGFR</i> L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohortStephen R Fairclough, Lesli A Kiedrowski, Jessica J Lin, et al.
Clinical Lung Cancer|November 12, 2019
Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung CancerSubba R Digumarthy, Dexter P Mendoza, Jessica J Lin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 24, 2024
Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief ReportSai-Hong Ignatius Ou, Benjamin J Solomon, Benjamin Besse, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 2, 2022
Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted TherapiesIbiayi Dagogo-Jack, Antonello Abbattista, John F Murphy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2019
Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLCIbiayi Dagogo-Jack, Marguerite Rooney, Rebecca J Nagy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 30, 2018
Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung CancerHarper G Hubbeling, Emily F Schapira, Nora K Horick, et al.
Pageof 10

Showing results (21-30 of 92) with videos related to

Sort By:
Pageof 10
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 12, 2018
Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS MetastasesJessica J Lin, Ginger Y Jiang, Nencyben Joshipura, et al.
JTO Clinical and Research Reports|August 18, 2025
Role of Quality of Life in Daily Functioning, Communication with Care Teams, and Treatment Decisions in Patients with <i>ALK</i>+ NSCLCHeather Law, Huamao M Lin, Eileen Curran, et al.
NPJ Precision Oncology|November 4, 2023
Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolutionJaime L Schneider, Khvaramze Shaverdashvili, Mari Mino-Kenudson, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2024
Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancerJessica R Bauman, Geoffrey Liu, Isabel Preeshagul, et al.
Experimental Hematology & Oncology|October 22, 2019
Identification of osimertinib-resistant <i>EGFR</i> L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohortStephen R Fairclough, Lesli A Kiedrowski, Jessica J Lin, et al.
Clinical Lung Cancer|November 12, 2019
Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung CancerSubba R Digumarthy, Dexter P Mendoza, Jessica J Lin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 24, 2024
Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief ReportSai-Hong Ignatius Ou, Benjamin J Solomon, Benjamin Besse, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 2, 2022
Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted TherapiesIbiayi Dagogo-Jack, Antonello Abbattista, John F Murphy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2019
Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLCIbiayi Dagogo-Jack, Marguerite Rooney, Rebecca J Nagy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 30, 2018
Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung CancerHarper G Hubbeling, Emily F Schapira, Nora K Horick, et al.
Pageof 10